All In Biotech

Drug Trial Radar · NCT07211165

Clinical Study on the Mass Balance of Clifutinib

Study on the Mass Balance of [14C] Clifutinib in Chinese Male Healthy Subjects

Last checked: Nov 19, 2026Latest source record: Jan 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

6

Actual

Start

Sep 29, 2025

Primary completion

Nov 5, 2025

Study completion Nov 12, 2025

Sponsor

Lead sponsor
Sunshine Lake Pharma Co., Ltd.Industry
Sponsor type
Industry
First posted
Oct 7, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To investigate the plasma total radioactivity PK characteristics of male healthy subjects after a single oral administration of \[14C\]Clifutinib, the distribution of total radioactivity in whole blood and plasma, and to determine the main excretion and metabolic pathways.

Conditions

  • Healthy Adult Male

Interventions

  • [14C]ClifutinibDrug

    The subjects are required to take the test drug on an empty stomach for at least 10 hours and without drinking water for 1 hour. After taking the drug, they should fast for 4 hours and refrain from drinking water for 1 hour.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. AUC0-∞Time frame: From Day 1 of dosing to the Day 85 after dosing
  2. TmaxTime frame: From Day 1 of dosing to the Day 85 after dosing
  3. CmaxTime frame: From Day 1 of dosing to the Day 85 after dosing
  4. Percentage of metabolites in plasma relative to total exposure AUC (% AUC)Time frame: From Day 1 of dosing to the Day 85 after dosing
  5. The total radioactivityTime frame: From Day 1 of dosing to the Day 85 after dosing
  6. Identification of major metabolites in plasma, urine, and fecal samplesTime frame: From Day 1 of dosing to the Day 85 after dosing

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Affiliated hospital of Jiangnan University

    Wuxi, Jiangsu, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.